Cardiovascular Effects of GLP-1 Receptor Activation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.

Also called NCT03101930

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 329 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03101930
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03101930. Randomized; quadruple masking; primary purpose basic science. Start 2017-05-01 (actual); primary completion 2021-06-24 (actual). Results posted on 2022-08-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Effects of GLP-1 Receptor Activation
Condition
Obesity
Condition
PreDiabetes
Intervention (Drug)
Liraglutide
Intervention (Drug)
Sitagliptin
Intervention (Other)
hypocaloric diet
Intervention (Drug)
Placebos
Intervention (Drug)
Exendin (9-39)
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
American Heart Association (class: other)

Record details

Record id
cardio:ct-nct03101930
Content hash
aecb57b61d5b937cd618d6547c5d58d40421c79a35758704c23f1087f8c6467e